Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial

  title={Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial},
  author={M. Privitera and T. Welty and B. Gidal and F. J. D{\'i}az and M. Berg},
  journal={The Lancet Neurology},
  • M. Privitera, T. Welty, +2 authors M. Berg
  • Published 2016
  • Medicine
  • The Lancet Neurology
  • BACKGROUND Patients and clinicians share concerns that generic drug substitution might lead to loss of efficacy or emergence of adverse events. In this trial, we assessed US Food and Drug Administration (FDA) bioequivalence standards by studying the effects of switching between two disparate generic immediate-release lamotrigine products in patients with epilepsy. METHODS The Equivalence among Generic Antiepileptic Drugs (EQUIGEN) chronic-dose study was a randomised, double-blind, crossover… CONTINUE READING
    58 Citations
    Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting
    • 10
    • Highly Influenced
    • PDF
    Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
    • 7
    • PDF
    Generic antiepileptic drugs—Safe or harmful in patients with epilepsy?
    • 12
    Generic antiepileptic drug equivalence: The journey from anecdotes to evidence
    • 1
    Lamotrigine add-on therapy for drug-resistant focal epilepsy.
    Switching generic antiepileptic drug manufacturer not linked to seizures
    • 27
    • PDF


    Generic Antiepileptic Drugs: Current Controversies and Future Directions
    • 48
    • PDF
    Antiepileptic drugs: generic versus branded treatments
    • 61
    Therapeutic equivalency of generic antiepileptic drugs: results of a survey
    • 112
    • PDF
    Generic substitution of antiepileptic drugs
    • 24